PDCD1 and neoplasm: A recently published clinical study found that the tumor immune barrier (TIB) structure, which involves SPP1+ macrophages and CAFs, is the primary structural feature related to immunotherapy resistance based on spatial transcriptomics (ST) and single-cell RNA-sequencing (scRNA-seq) data from patients receiving anti-PD-1 treatment [130].